Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma

Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific targeting, the concentration of the drug in tumor tissue cannot be permanently maintained at a level that i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Drug Deliv
Glavni autori: Tang, Xiaolong, Chen, Longzhou, Li, Amin, Cai, Shiyu, Zhang, Yinci, Liu, Xueke, Jiang, Zhenyou, Liu, Xinkuang, Liang, Yong, Ma, Dong
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058710/
https://ncbi.nlm.nih.gov/pubmed/29916268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2018.1477859
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items